Success Metrics

Clinical Success Rate
83.3%

Based on 5 completed trials

Completion Rate
83%(5/6)
Active Trials
3(30%)
Results Posted
80%(4 trials)
Terminated
1(10%)

Phase Distribution

Ph phase_2
3
30%
Ph phase_4
1
10%
Ph phase_1
3
30%
Ph phase_3
3
30%

Phase Distribution

3

Early Stage

3

Mid Stage

4

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
3(30.0%)
Phase 2Efficacy & side effects
3(30.0%)
Phase 3Large-scale testing
3(30.0%)
Phase 4Post-market surveillance
1(10.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

83.3%

5 of 6 finished

Non-Completion Rate

16.7%

1 ended early

Currently Active

3

trials recruiting

Total Trials

10

all time

Status Distribution
Active(4)
Completed(5)
Terminated(1)

Detailed Status

Completed5
Recruiting2
Terminated1
Active, not recruiting1
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
3
Success Rate
83.3%
Most Advanced
Phase 4

Trials by Phase

Phase 13 (30.0%)
Phase 23 (30.0%)
Phase 33 (30.0%)
Phase 41 (10.0%)

Trials by Status

completed550%
recruiting220%
terminated110%
active_not_recruiting110%
not_yet_recruiting110%

Recent Activity

3 active trials
Showing 5 of 10
not_yet_recruitingphase_1

A Phase I Clinical Trial to Assess the Safety and Immunogenicity of DX-104

NCT07395739
recruitingphase_3

Research Trial Assessing the Immunogenicity and Safety of Three Meningococcal B Vaccine Strategies Among Patients With Asplenia.

NCT04166656
active_not_recruitingphase_3

BIYELA - Bexsero Immunisation in Young Women in Africa

NCT06446752
completedphase_1

A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes

NCT06033261
recruitingphase_2

Meningococcal B Vaccine in Patients with Asplenia

NCT06025487
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT07395739Phase 1

A Phase I Clinical Trial to Assess the Safety and Immunogenicity of DX-104

Not Yet Recruiting
NCT04166656Phase 3

Research Trial Assessing the Immunogenicity and Safety of Three Meningococcal B Vaccine Strategies Among Patients With Asplenia.

Recruiting
NCT06446752Phase 3

BIYELA - Bexsero Immunisation in Young Women in Africa

Active Not Recruiting
NCT06033261Phase 1

A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes

Completed
NCT06025487Phase 2

Meningococcal B Vaccine in Patients with Asplenia

Recruiting
NCT04645966Phase 2

A Clinical Trial to Assess the Safety, Tolerability and Immunogenicity of MenABCWY in Healthy Infants

Terminated
NCT02173704Phase 3

Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Meningococcal B Recombinant Vaccine When Administered Concomitantly With Routine Vaccines to Healthy Infants of 2 Months of Age and Older, in Taiwan.

Completed
NCT02212457Phase 2

Trial to Assess Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Meningococcal ABCWY Vaccine as Compared to Meningococcal B Vaccine in Adolescents

Completed
NCT02583412Phase 4

Pilot Study of the Immunogenicity, Reactogenicity and Tolerability of Two Schedules of a 4CmenB Vaccine in Adolescents and Young Adults

Completed
NCT02491463Phase 1

A Study to Assess the Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' RSV Investigational Vaccine (ChAd155-RSV) (GSK3389245A) in Healthy Adults

Completed

All 10 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
10